Association of BAL Fluid T-Cell Immune Activity With Tumor PD-L1 Expression and Its Prognostic Value: A Prospective Observational Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-01-31

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective observational study aims to evaluate whether immune profiles of T-cell subsets in bronchoalveolar lavage fluid can complement tumor PD-L1 expression, assessed by immunohistochemistry in tumor tissue specimens, in predicting clinical outcomes in patients with advanced lung cancer. Although tumor PD-L1 expression measured on tissue biopsies is widely used to guide immunotherapy decisions, its predictive value is limited by spatial heterogeneity and sampling variability. By analyzing activated, exhausted, and regulatory T-cell populations in bronchoalveolar lavage fluid and examining their association with tissue-based tumor PD-L1 expression, this study seeks to determine whether combining local immune biomarkers with PD-L1 expression improves the prediction of treatment response and survival in patients receiving standard-of-care systemic therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC Patients

NCT04312308

Non Small Cell Lung Cancer

COMPLETED

Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC

NCT04372732

Lung Cancer Immunotherapy

UNKNOWN

The Correlation of PD-L1 Expression in Non-small Lung Cancer Tissue and Peripheral Blood T Cell and Serum.

NCT03073902

NSCLC

COMPLETED

irAE Prediction of Anti-PD-1/L1 in Lung Cancer

NCT05288569

Immune Checkpoint Inhibitors Lung Cancer

UNKNOWN

Exploratory Biomarker Analysis of Neoadjuvant Chemoimmunotherapy Followed by Pulmonary Resection in Stage II-III Non-Small Cell Lung Cancer

NCT06907160

Clinical Stage II to III Non-Small Cell Lung Cancer

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Tumor PD-L1 expression assessed by immunohistochemistry on tumor tissue specimens is an established biomarker for selecting immune checkpoint inhibitor therapy in lung cancer; however, its clinical utility is limited by intratumoral heterogeneity, temporal variability, and dependence on the size and location of tissue biopsy samples. As a result, tissue-based PD-L1 expression alone does not fully capture the immune context of the tumor microenvironment or reliably predict treatment response and prognosis in all patients.

Bronchoalveolar lavage fluid provides access to the local pulmonary immune microenvironment and contains immune cells that may reflect tumor-immune interactions more directly than peripheral blood. Prior studies suggest that T-cell populations in bronchoalveolar lavage fluid share phenotypic characteristics with tumor-infiltrating lymphocytes and may serve as surrogate indicators of local antitumor immune activity. However, the relationship between bronchoalveolar lavage T-cell immunophenotypes, tissue-based tumor PD-L1 expression, and clinical outcomes has not been comprehensively evaluated in a prospective setting.

This single-center prospective observational cohort study enrolls adult patients with suspected or confirmed stage IV lung cancer who are undergoing clinically indicated bronchoscopy as part of routine diagnostic or management procedures. Residual bronchoalveolar lavage fluid obtained during standard-of-care bronchoscopy is analyzed using multicolor flow cytometry to quantify T-cell subsets, including activated, exhausted, and regulatory populations defined by surface marker expression. Tumor PD-L1 expression is evaluated by immunohistochemistry performed on diagnostic tumor tissue specimens obtained as part of routine clinical care and analyzed both as a continuous variable and by predefined expression categories.

Participants receive standard systemic anticancer therapy according to current clinical guidelines, including immune checkpoint inhibitor-based regimens when indicated. Clinical outcomes, including objective response rate, progression-free survival, and overall survival, are prospectively collected from electronic medical records. The study examines correlations between bronchoalveolar lavage T-cell immunophenotypes and tissue-based tumor PD-L1 expression, as well as whether stratification based on combined immune profiling provides improved prognostic information compared with tumor PD-L1 expression alone.

By integrating local immune profiling from bronchoalveolar lavage fluid with tumor PD-L1 expression assessed in tissue specimens, this study seeks to identify complementary biomarkers that may enhance risk stratification and refine prognostic assessment in advanced lung cancer, potentially informing future approaches to personalized immunotherapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Neoplasms Tumor Immune Microenvironment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Advanced Lung Cancer Cohort

Adults with suspected or confirmed stage IV lung cancer undergoing clinically indicated bronchoscopy with bronchoalveolar lavage. Participants are enrolled prospectively as a single observational cohort, and no treatment assignment or intervention is determined by the study. Bronchoalveolar lavage fluid is collected for immune profiling by flow cytometry, and study analyses stratify participants post hoc according to tumor PD-L1 expression levels and bronchoalveolar lavage T-cell immunophenotypes.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults aged 19 years or older
* Patients with suspected or histologically confirmed stage IV lung cancer based on clinical and radiologic findings
* Scheduled to undergo clinically indicated bronchoscopy with bronchoalveolar lavage as part of routine clinical care
* Able and willing to provide written informed consent

Exclusion Criteria

* Receipt of treatment for acute lower respiratory tract infection (including pneumonia or fungal infection) within 4 weeks prior to bronchoscopy
* History of solid organ transplantation or hematopoietic stem cell transplantation
* Current use of systemic immunosuppressive therapy
* Current or planned use of biologic immunomodulatory agents
* Known autoimmune disease requiring systemic immunosuppressive treatment
* Pregnant women
* Patients with recurrent stage IV lung cancer after prior definitive therapy

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No